NCT Number: NCT01734668
Sofia RSV FIA Field Study
The objective of this study is to demonstrate the clinical performance of the Sofia RSV FIA with specimens from symptomatic pediatric subjects who are less than nineteen (19) years of age.
Looking for future studies?
Notify MeKey information
Conditions
Age range
Up to 18 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Best Medical Group, Phoenix, Arizona, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or Female
- Children less than nineteen (19) years of age can participate (assuming appropriate consent is obtained).
- Must currently be exhibiting symptoms characteristic of respiratory syncytial virus (RSV) illness.
- Subjects must present with one or more of the following to be eligible for enrollment:
- Fever, ≥ 37.8º C (100º F) at present or within past 24 hours
- Moderate to severe runny nose*
- Moderate to severe congestion*
- Decreased appetite
- Coughing
- Sneezing*
- Wheezing
- Irritability
- Decreased activity
- Labored breathing
Exclusion criteria
- Subjects nineteen years of age or older.
- The parent or legal guardian is unable to understand and consent to participation.
- Current or prior treatment during this infection with anti-RSV Synagis®.
Treatment and study plan
Primary outcomes
-
High level of sensitivity and specificity for performance vs. culture
Time frame: Culture results within 48 hours of plating
Clinical performance will be based on comparison of the Sofia RSV FIA results to cell culture.
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Quidel Corporation
Industry
Registry information
Important dates
- Study start
- 2012
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Nov 28, 2012
- Registry last updated
- Feb 7, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
NCT06067230
Infections, Respiratory Syncytial Virus
Glendale, Arizona, United States
View Trial DetailsA Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
NCT06097299
Infections, Respiratory Syncytial Virus
Phoenix, Arizona, United States
View Trial DetailsA Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
NCT06325657
Infections, Respiratory Syncytial Virus
East London, Eastern Cape, South Africa
View Trial DetailsA Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
NCT06143046
Infections, Respiratory Syncytial Virus
Dothan, Alabama, United States
View Trial Details